S&P 500   4,267.52
DOW   33,665.02
QQQ   348.82
Stock market today: Asian shares slip following technology selloff on Wall Street
The single greatest medical breakthrough of all time? (Ad)
Tesla: How and Why It Gets To $300
Don't Overlook Hidden Gem Kinsale As Rallies To New Highs
BREAKING: Tiny biotech successfully treats blindness (Ad)
AI-powered IoT Automation is Driving Samsara To New Highs
What is a Growth Stock Mutual Fund?
The single greatest medical breakthrough of all time? (Ad)
Sprinklr Gets Targets Raised By Analysts, Here's Why
Time To Buy Uranium? Cameco Is The Top Pick
S&P 500   4,267.52
DOW   33,665.02
QQQ   348.82
Stock market today: Asian shares slip following technology selloff on Wall Street
The single greatest medical breakthrough of all time? (Ad)
Tesla: How and Why It Gets To $300
Don't Overlook Hidden Gem Kinsale As Rallies To New Highs
BREAKING: Tiny biotech successfully treats blindness (Ad)
AI-powered IoT Automation is Driving Samsara To New Highs
What is a Growth Stock Mutual Fund?
The single greatest medical breakthrough of all time? (Ad)
Sprinklr Gets Targets Raised By Analysts, Here's Why
Time To Buy Uranium? Cameco Is The Top Pick
S&P 500   4,267.52
DOW   33,665.02
QQQ   348.82
Stock market today: Asian shares slip following technology selloff on Wall Street
The single greatest medical breakthrough of all time? (Ad)
Tesla: How and Why It Gets To $300
Don't Overlook Hidden Gem Kinsale As Rallies To New Highs
BREAKING: Tiny biotech successfully treats blindness (Ad)
AI-powered IoT Automation is Driving Samsara To New Highs
What is a Growth Stock Mutual Fund?
The single greatest medical breakthrough of all time? (Ad)
Sprinklr Gets Targets Raised By Analysts, Here's Why
Time To Buy Uranium? Cameco Is The Top Pick
S&P 500   4,267.52
DOW   33,665.02
QQQ   348.82
Stock market today: Asian shares slip following technology selloff on Wall Street
The single greatest medical breakthrough of all time? (Ad)
Tesla: How and Why It Gets To $300
Don't Overlook Hidden Gem Kinsale As Rallies To New Highs
BREAKING: Tiny biotech successfully treats blindness (Ad)
AI-powered IoT Automation is Driving Samsara To New Highs
What is a Growth Stock Mutual Fund?
The single greatest medical breakthrough of all time? (Ad)
Sprinklr Gets Targets Raised By Analysts, Here's Why
Time To Buy Uranium? Cameco Is The Top Pick
Top-Rated StocksTop-Rated
NASDAQ:ITCI

Intra-Cellular Therapies (ITCI) Earnings Date, Estimates & Call Transcripts

$65.13
-0.28 (-0.43%)
(As of 06/7/2023 ET)
Compare
Today's Range
$63.46
▼
$65.72
50-Day Range
$54.15
▼
$66.44
52-Week Range
$42.01
▼
$66.56
Volume
1.01 million shs
Average Volume
788,078 shs
Market Capitalization
$6.25 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$74.82
ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainability

Earnings Summary

Upcoming
Earnings Date
Aug. 8Estimated
Actual EPS
(May. 4)
-$0.46 Beat By $0.17
Consensus EPS
(May. 4)
-$0.63
Last Year's Q2 EPS
(5/10/2022)
-$0.78
Read Call Transcript
Listen to Call
Skip Charts & View Estimated and Actual Earnings Data
Earnings Per ShareRevenue

ITCI Earnings Estimates and Actuals by Quarter

The chart below shows up to four years of a company's earnings history. The dark blue line represents the company's actual earnings per share. The light blue area represents the range of Wall Street analysts' earnings estimates for each quarter.

ITCI Estimated and Actual Revenue by Quarter

The chart below shows up to four years of a company's revenue history. The dark blue line represents the company's actual revenue. The light blue line represents the company's estimated revenue based on the consensus of Wall Street analysts for each quarter.

Intra-Cellular Therapies Analyst Forecasts

QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20232($0.64)($0.54)($0.59)
Q2 20232($0.64)($0.56)($0.60)
Q3 20232($0.59)($0.56)($0.58)
Q4 20232($0.61)($0.51)($0.56)
FY 20238($2.48)($2.17)($2.33)

ITCI Earnings Date and Information

Intra-Cellular Therapies last issued its earnings results on May 4th, 2023. The biopharmaceutical company reported ($0.46) earnings per share for the quarter, topping analysts' consensus estimates of ($0.63) by $0.17. The business had revenue of $95.31 million for the quarter, compared to the consensus estimate of $92.14 million. Intra-Cellular Therapies has generated ($2.40) earnings per share over the last year (($2.40) diluted earnings per share). Earnings for Intra-Cellular Therapies are expected to grow in the coming year, from ($2.32) to ($1.12) per share. Intra-Cellular Therapies has not formally confirmed its next earnings publication date, but the company's estimated earnings date is Tuesday, August 8th, 2023 based off prior year's report dates.

Intra-Cellular Therapies Earnings History by Quarter

Export to Excel
DateQuarterConsensus EstimateReported EPSBeat/MissGAAP EPSRevenue EstimateActual RevenueCall Transcript
8/8/2023
(Estimated)		        
5/4/2023Q1 2023($0.63)($0.46)+$0.17($0.46)$92.14 million$95.31 million    
3/1/2023Q4 2022($0.62)($0.45)+$0.17($0.45)$86.97 million$87.87 million    
11/3/2022Q3 2022($0.86)($0.57)+$0.29($0.57)$64.95 million$71.87 million
8/9/2022Q2 2022($0.79)($0.92)($0.13)($0.92)$48.62 million$55.58 million    
5/10/2022Q1 2022($0.93)($0.78)+$0.15($0.78)$33.52 million$35.00 million    
3/1/2022Q4 2021($1.05)($1.05)($1.05)$24.93 million$25.67 million    
11/8/20219/30/2021($0.92)($0.95)($0.03)($0.95)$22.11 million$22.21 million    
8/8/20216/30/2021($0.79)($0.85)($0.06)($0.85)$19.04 million$20.00 million    
5/9/20213/31/2021($0.81)($0.65)+$0.16($0.65)$15.74 million$15.88 million  
2/24/202112/31/2020($0.85)($0.76)+$0.09($0.76)$12.45 million$12.45 million  
11/14/20209/30/2020($1.00)($0.79)+$0.21($0.79)$6.52 million$7.37 million  
8/10/20206/30/2020($0.94)($0.96)($0.02)($0.96)$3.05 million$1.91 million  
5/7/20203/31/2020($0.93)($0.73)+$0.20($0.73)$1.75 million$1.08 million  
3/2/2020Q4 2019($0.81)($0.74)+$0.07($0.74)$0.06 million  
11/5/2019Q3 2019($0.80)($0.63)+$0.17($0.63)  
8/7/2019Q2 2019($0.8310)($0.68)+$0.1510($0.68)
5/8/20193/31/2019($0.90)($0.63)+$0.27($0.63)
2/27/2019Q4 2018($0.84)($0.75)+$0.09($0.75)
11/7/20189/30/2018($0.85)($0.76)+$0.09($0.76)
8/2/2018Q2 2018($0.76)($0.68)+$0.08($0.68)
5/3/2018Q1 2018($0.6630)($0.6490)+$0.0140($0.65)$0.10 million
3/1/2018n/a($0.50)($0.56)($0.06)($0.56)$0.05 million$5.06 million
11/8/2017Q3 2017($0.53)($0.5270)+$0.0030($0.53)$0.06 million$0.03 million
8/9/2017Q2 2017($0.74)($0.41)+$0.33($0.41)$0.03 million$0.11 million
5/10/2017Q1 2017($0.74)($0.62)+$0.12($0.62)$0.02 million$0.10 million
3/1/2017Q4 2016($0.77)($0.64)+$0.13($0.64)$0.10 million$0.10 million  
11/9/2016Q316($0.84)($0.70)+$0.14($0.70)$0.04 million$4.36 million  
8/4/2016Q216($0.79)($0.71)+$0.08($0.71)$0.02 million$0.23 million
4/28/2016Q116($0.78)($0.64)+$0.14($0.64)$0.02 million  
2/25/2016Q415($0.84)($0.67)+$0.17($0.67)$0.05 million$30.66 million  
11/5/2015Q315($0.66)($0.91)($0.25)($0.91)$0.10 million
8/5/2015Q215($0.72)($0.61)+$0.11($0.61)$40.00 million$57.40 million
4/30/2015Q1($0.68)($0.72)($0.04)($0.72)
3/12/2015Q4 2014($0.49)($0.52)($0.03)($0.52)$0.07 million
11/3/2014Q314($0.34)($0.22)+$0.12($0.22)$0.12 million  
8/12/2014Q214($0.24)($0.15)+$0.09($0.15)$0.22 million
5/5/2014Q1 2014($0.23)($0.17)+$0.06($0.17)$0.17 million
3/25/2014Q4 2013($0.41)($0.36)+$0.05($0.36)$0.60 million$0.83 million
11/5/2013Q3 2013($0.23)($0.42)($0.19)($0.42)$0.67 million












Intra-Cellular Therapies Earnings - Frequently Asked Questions

When is Intra-Cellular Therapies's earnings date?

Intra-Cellular Therapies has not confirmed its next earnings publication date, but the company's estimated earnings date is Tuesday, August 8th, 2023 based off last year's report dates. Learn more on ITCI's earnings history.

Did Intra-Cellular Therapies beat their earnings estimates last quarter?

In the previous quarter, Intra-Cellular Therapies (NASDAQ:ITCI) reported ($0.46) earnings per share (EPS) to beat the analysts' consensus estimate of ($0.63) by $0.17. Learn more on analysts' earnings estimate vs. ITCI's actual earnings.

How can I listen to Intra-Cellular Therapies's earnings conference call?

The conference call for Intra-Cellular Therapies's latest earnings report can be listened to online. Listen to Conference Call

How can I read Intra-Cellular Therapies's conference call transcript?

The conference call transcript for Intra-Cellular Therapies's latest earnings report can be read online. Read Transcript

How much revenue does Intra-Cellular Therapies generate each year?

Intra-Cellular Therapies (NASDAQ:ITCI) has a recorded annual revenue of $250.31 million.

How much profit does Intra-Cellular Therapies generate each year?

Intra-Cellular Therapies (NASDAQ:ITCI) has a recorded net income of -$256.26 million. ITCI has generated -$2.40 earnings per share over the last four quarters.

What is Intra-Cellular Therapies's EPS forecast for next year?

Intra-Cellular Therapies's earnings are expected to grow from ($2.32) per share to ($1.12) per share in the next year.

More Earnings Resources from MarketBeat

Related Companies:
Earnings Tools:
Earnings By Country:
Latest Articles:
This page (NASDAQ:ITCI) was last updated on 6/8/2023 by MarketBeat.com Staff

My Account -